UY33503A - Imidazo [1,2-a]pirimidinas y piridinas sustituidas - Google Patents
Imidazo [1,2-a]pirimidinas y piridinas sustituidasInfo
- Publication number
- UY33503A UY33503A UY0001033503A UY33503A UY33503A UY 33503 A UY33503 A UY 33503A UY 0001033503 A UY0001033503 A UY 0001033503A UY 33503 A UY33503 A UY 33503A UY 33503 A UY33503 A UY 33503A
- Authority
- UY
- Uruguay
- Prior art keywords
- pyridins
- pyrimidins
- imidazo
- replaced
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10169205 | 2010-07-12 | ||
| US39277910P | 2010-10-13 | 2010-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33503A true UY33503A (es) | 2012-02-29 |
Family
ID=44532777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001033503A UY33503A (es) | 2010-07-12 | 2011-07-11 | Imidazo [1,2-a]pirimidinas y piridinas sustituidas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8975265B2 (OSRAM) |
| EP (1) | EP2593451B1 (OSRAM) |
| JP (1) | JP5830094B2 (OSRAM) |
| CN (1) | CN103097384B (OSRAM) |
| AR (1) | AR090005A1 (OSRAM) |
| CA (1) | CA2804845A1 (OSRAM) |
| ES (1) | ES2552841T3 (OSRAM) |
| TW (1) | TW201206933A (OSRAM) |
| UY (1) | UY33503A (OSRAM) |
| WO (1) | WO2012007345A2 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2567605T3 (es) * | 2011-04-06 | 2016-04-25 | Taiho Pharmaceutical Co., Ltd. | Nuevo compuesto de imidazo-oxazina o sal del mismo |
| EA024890B1 (ru) * | 2011-04-07 | 2016-10-31 | Байер Интеллектчуал Проперти Гмбх | Имидазопиридазины в качестве ингибиторов akt киназы |
| WO2013104610A1 (en) * | 2012-01-10 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines as akt kinase inhibitors |
| CN104066736B (zh) * | 2012-01-10 | 2017-03-08 | 拜耳知识产权有限责任公司 | 作为akt激酶抑制剂的取代的吡唑并嘧啶 |
| US9309243B2 (en) * | 2012-07-13 | 2016-04-12 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| NZ723203A (en) | 2014-02-13 | 2020-08-28 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016136928A1 (ja) | 2015-02-27 | 2016-09-01 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
| UA122688C2 (uk) | 2015-04-03 | 2020-12-28 | Інсайт Корпорейшн | Гетероциклічні сполуки як інгібітори lsd1 |
| CN106188063A (zh) * | 2015-05-08 | 2016-12-07 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途 |
| JP7427363B2 (ja) | 2015-08-12 | 2024-02-05 | インサイト・ホールディングス・コーポレイション | Ｌｓｄ１阻害剤の塩 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| US10166221B2 (en) | 2016-04-22 | 2019-01-01 | Incyte Corporation | Formulations of an LSD1 inhibitor |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| GB201811695D0 (en) * | 2018-07-17 | 2018-08-29 | Salvensis | Compounds for use in the treatment of fascioliasis |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| CN109734713B (zh) * | 2019-03-07 | 2021-06-04 | 东华理工大学 | 一种3-亚胺基咪唑并[1,2-a]吡啶化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006258124B8 (en) * | 2005-06-10 | 2010-01-07 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| DE602008005894D1 (de) * | 2007-08-14 | 2011-05-12 | Bayer Schering Pharma Ag | Kondensierte imidazole zur krebsbehandlung |
| BRPI0908906A2 (pt) | 2008-03-21 | 2019-09-24 | Novartis Ag | compostos heterocíclicos e usos dos mesmos |
| AU2009255358A1 (en) * | 2008-06-03 | 2009-12-10 | Msd K.K. | Inhibitors of Akt activity |
| WO2010088177A1 (en) | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2405756B1 (en) | 2009-03-12 | 2013-07-03 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2473495A1 (en) | 2009-09-18 | 2012-07-11 | Almac Discovery Limited | Pharmaceutical compounds |
| GB0919380D0 (en) | 2009-11-04 | 2009-12-23 | Almac Discovery Ltd | Pharmaceutical compouds |
-
2011
- 2011-07-07 JP JP2013519035A patent/JP5830094B2/ja not_active Expired - Fee Related
- 2011-07-07 WO PCT/EP2011/061508 patent/WO2012007345A2/en not_active Ceased
- 2011-07-07 US US13/808,430 patent/US8975265B2/en not_active Expired - Fee Related
- 2011-07-07 CN CN201180043391.XA patent/CN103097384B/zh not_active Expired - Fee Related
- 2011-07-07 ES ES11730003.8T patent/ES2552841T3/es active Active
- 2011-07-07 CA CA2804845A patent/CA2804845A1/en not_active Abandoned
- 2011-07-07 EP EP11730003.8A patent/EP2593451B1/en active Active
- 2011-07-11 UY UY0001033503A patent/UY33503A/es not_active Application Discontinuation
- 2011-07-12 AR ARP110102496A patent/AR090005A1/es unknown
- 2011-07-12 TW TW100124649A patent/TW201206933A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012007345A3 (en) | 2012-04-12 |
| WO2012007345A2 (en) | 2012-01-19 |
| US20130190332A1 (en) | 2013-07-25 |
| JP2013531684A (ja) | 2013-08-08 |
| JP5830094B2 (ja) | 2015-12-09 |
| AR090005A1 (es) | 2014-10-15 |
| CN103097384B (zh) | 2017-02-15 |
| ES2552841T3 (es) | 2015-12-02 |
| CA2804845A1 (en) | 2012-01-19 |
| EP2593451B1 (en) | 2015-08-19 |
| CN103097384A (zh) | 2013-05-08 |
| EP2593451A2 (en) | 2013-05-22 |
| TW201206933A (en) | 2012-02-16 |
| US8975265B2 (en) | 2015-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14013284A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| WO2012007345A3 (en) | Substituted imidazo[1,2-a]pyrimidines and -pyridines | |
| SV2017005487A (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| CR20130213A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogènesis | |
| UY33801A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III | |
| MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
| UY33890A (es) | Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa | |
| ECSP12011855A (es) | COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA | |
| CO6511228A2 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| GT201200321A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
| CL2012002270A1 (es) | Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer. | |
| CO6450612A2 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| CU20140089A7 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP11011258A (es) | Pirimidinas fusionadas | |
| UY35467A (es) | Compuestos orgánicos | |
| UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
| CR20140031A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| GT201500094A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| GT201400090A (es) | 2-tiopirimidinonas | |
| ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
| CU20130124A7 (es) | Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia | |
| UY34273A (es) | Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20200807 |